Ownership and insider activity for BioVie Inc. (BIVI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
Price
| Price | $1.72 |
| Market Cap | $13M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-28 | Palumbo Joseph M | P-Purchase | 4,843 | $10K |
| 2026-08-28 | Chappell Amy Suzon | P-Purchase | 727 | $2K |
| 2026-08-28 | KIM JOANNE WENDY | P-Purchase | 2,500 | $5K |
| 2026-08-27 | DO CUONG V | P-Purchase | 15,210 | $32K |
| 2026-01-05 | Palumbo Joseph M | A-Award | 132,000 | $173K |
| 2026-01-05 | KIM JOANNE WENDY | A-Award | 110,100 | $144K |
| 2026-01-05 | ROGICH SIGMUND | A-Award | 141,100 | $185K |
| 2026-01-05 | ROGICH SIGMUND | A-Award | 70,000 | $92K |
| 2026-01-05 | DO CUONG V | A-Award | 665,300 | $872K |
| 2026-01-05 | Sherman Michael Edward | A-Award | 341,100 | $447K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5140 | $45800 | $339923 | $37195 | $4.5M | $18.6M | $19.5M | $23.8M | $17.5M | $8.98T |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $14.5M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.1M | $2.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $5140 | $45800 | $674073 | $412980 | $4.6M | $18.8M | $34.0M | $24.0M | $20.7M | $13.64T |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | $118254 | $80789 | $406726 | $339653 | $262.59B |
| Goodwill | $345711 | $345711 | $345711 | $345711 | $345711 | $345711 | $345711 | $345711 | $345711 | $345.71B |
| Intangible Assets | $2.0M | $1.8M | $1.6M | $1.3M | $1.1M | $866472 | $637095 | $407718 | $178341 | 0 |
| Total Assets | $2.4M | $2.2M | $2.6M | $2.1M | $6.0M | $20.1M | $35.1M | $25.2M | $21.6M | $14.25T |
| Accounts Payable | $470973 | $884207 | $443480 | $1.3M | $996374 | $2.4M | 0 | 0 | 0 | $3.7M |
| Short-term Debt | $35000 | 0 | 0 | $848543 | 0 | 0 | $9.1M | $5.7M | 0 | $91.01B |
| Total Current Liabilities | $630973 | $1.2M | $443480 | $23.5M | $996374 | $4.2M | $14.5M | $9.4M | $2.3M | $3.80T |
| Long-term Debt | $575918 | $825918 | 0 | $62500 | 0 | $12.1M | $5.2M | 0 | 0 | $184.42B |
| Total Liabilities | $1.2M | $2.1M | $443480 | $23.6M | $996374 | $16.4M | $19.8M | $9.7M | $2.6M | $3.98T |
| Retained Earnings | -$2.3M | -$4.8M | -$7.3M | -$41.0M | -$224.9M | -$251.0M | -$301.2M | -$334.2M | -$352.1M | -$374.26T |
| Total Equity | $1.2M | $111199 | $2.1M | -$21.5M | $5.1M | $3.7M | $15.3M | $15.5M | $19.0M | $10.27T |
| Total Debt | $35000 | $825918 | 0 | $911043 | 0 | $12.3M | $14.4M | $6.1M | $349894 | $275.43B |
| Net Debt | $29860 | $780118 | -$339923 | $873848 | -$4.5M | -$6.4M | -$19.5M | -$17.7M | -$17.2M | -$8.70T |
| Working Capital | -$625833 | -$1.2M | $230593 | -$23.1M | $3.6M | $14.6M | $19.5M | $14.7M | $18.4M | $9.85T |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 3.59 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -21.39 |
Profitability
| Return on Equity | -126.02% |
| Return on Invested Capital | -214.80% |
| Return on Assets | -154.89% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTL · CANF · CERO · ELAB · GLMD · INM · KZIA
Explore sector: Healthcare · Biotechnology
More sections of BIVI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks